UNASSIGNED: 7317 Background: Previously we reported an enhanced effectiveness of chemotherapy in induction therapy of @entity5 following a relatively low dose(20 Gy) of radiation therapy (Proc ASCO 18:524a, 1999): The response rate was 91 % (11/12 @entity1 ). METHODS: Newly diagnosed @entity1 with stage IB - IIIB @entity4153 entered the study. The treatment consisted of 20 Gy of radiation therapy in 10 fractions to the primary and the mediastinum. This was followed by 2 courses of chemotherapy with @entity1311 180 mg/m2 intravenously (IV) in 3 hours; @entity900 45 mg/m2 IV in 6 hours; and @entity1260 1,000 mg/m2 IV in 6 hours. The @entity1 were reassessed and if suitable the surgical therapy was advised. RESULTS: From March 2000 to July 2003, thirty two @entity1 entered the study.They were 11 @entity1 with stage IB-IIB, and 21 @entity1 with stage IIIA and B. The age ranged from 40 to 78 years.The performance status was 0 and 1. Grade    @entity1431 noted in 9 @entity1 (one grade 4). Five @entity1 received @entity1261 . In 27 @entity1 (84.38%) response was noted (confidence interval,CI 67.21 - 94.72%). Complete response (CR) was in 7 @entity1 (21.88 %) (CI 9.28 - 39.97 %). In addition, 3 @entity1 had a pathological CR of the surgically removed specimen thus the CR (clinical + pathological) rate was 10/32 (31.25%) (CI 16.12 - 50.01 %). Twenty two @entity1 subsequently had the surgical therapy. Seven @entity1 with CR and ten @entity1 post operatively completed the remaining course of radiation therapy (45 Gy). There was no surgical mortality, one @entity1 died of @entity358 after completing the full course of radiation (stage IIIA).The median follow up time is 21 months and the median survival was not observed but is estimated to be greater than 46 months. The 2 year survival of @entity1 with stage IB - IIB is 57.14 %, and that of stage III (A and B) is 61.54 %. CONCLUSIONS: Induction therapy using radiation induced sensitization of chemotherapy produced a high response rate with a low treatment related mortality (3.7 %), and appears to be a suitable regimen for induction therapy for the locoregional @entity4153 including earlier stage. No significant financial relationships to disclose.

Induction therapy for @entity4153 ( XXXX ) using the principle of radiation therapy induced sensitization to chemotherapy: A phase II study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity4153 :: ('MESH:D018288', 'Disease') :: ['NSCLC'] @entity1261 :: ('1440', 'Gene') :: ['granulocyte colony stimulating factor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['stage III lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['taxol'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide']
@entity4153 :: (MESH:D018288,Disease) :: ['NSCLC']
